Dr. Ohnuma's research laboratory, for a number of years, has focused on carrying out cellular, biochemical and molecular pharmacological investigations of cancer therapeutics. During the past year, two projects have been emphasized, the development of ribozyme strategy against deletion-mutant EGFR in the treatment of human glioblastoma multiforme, and the examination of reovirus as an anticancer agent.